98%
921
2 minutes
20
Background: Necrotizing enterocolitis (NEC) is a rapidly progressive and severe gastrointestinal disorder in neonates that is marked by an inflammatory cascade initiated by mechanisms that remain incompletely understood, resulting in intestinal necrosis and systemic infections. This study demonstrated that itaconate (ITA) exerts a protective effect in NEC by regulating macrophage reprogramming.
Methods: Changes in ITA expression were investigated using immunofluorescence staining and liquid chromatography-mass spectrometry, and their effect on immune cell differentiation was verified through single-cell sequencing. In vivo experiments were performed using ACOD1 and ACOD1LysM NEC mouse models.
Results: We detected changes in ITA expression in clinical NEC samples and confirmed the effect of these changes on immune cell differentiation. In vivo experiments confirmed the therapeutic role of ITA in regulating macrophage differentiation in NEC, and we further investigated the mechanism by which ITA regulates macrophage metabolic reprogramming. The depletion of ITA in NEC correlates with an increased frequency of pro-inflammatory macrophage polarization, thereby exacerbating intestinal inflammatory injury. Importantly, our in vivo experiments revealed that treatment with 4-octyl itaconate (4OI) significantly mitigated intestinal symptoms associated with NEC in murine models. Mechanistic investigations showed that 4OI effectively suppressed M1 macrophage polarization by rescuing mitochondrial function and upregulating oxidative phosphorylation in macrophages.
Conclusions: Our results highlight ITA as a metabolic checkpoint of macrophage differentiation in NEC and suggest the therapeutic efficacy of 4OI in NEC.
Key Points: Itaconate alleviates NEC by reprogramming M1 macrophage metabolism ACOD1 deficiency exacerbates NEC severity 4OI maintains intestinal barrier integrity. 4OI rescues NEC by regulating macrophage mitochondrial activity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268792 | PMC |
http://dx.doi.org/10.1002/ctm2.70419 | DOI Listing |
Phytochemistry
September 2025
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Natural Products Research Center of Guizhou Province, Guiyang 550014, China. Electronic address:
Seven previously undescribed glycosides, including four iridoid glycosides (1, 2, 4, and 5), three phenolic glucosides (18, 21, and 22), together with nineteen known compounds, were isolated from the ethanol extract of Gentiana rhodantha Franch. Their structures were determined by analysis of 1D and 2D NMR, HRESIMS, X-ray diffraction, NMR calculation, and electronic circular dichroism (ECD) calculation. Among them, compound 21 was a novel highly rearranged endo-phenolic analogue with a unique skeleton.
View Article and Find Full Text PDFJ Ethnopharmacol
September 2025
School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, 102400, China. Electronic address:
Ethnopharmacological Relevance: Fever is a prevalent clinical symptom and is usually caused by inflammation or infection. Persistent high fever can lead to delirium, coma and convulsions, causing brain damage. Angong Niuhuang Pill (ANP), a traditional Chinese emergency medicine, has been employed in clinical practice for centuries, with well-documented antipyretic effects.
View Article and Find Full Text PDFJ Ethnopharmacol
September 2025
National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. Electronic address:
Ethnopharmacological Relevance: Both chuanxiong rhizome and Coptis chinensis were first recorded in the Shennong's Classic of Materia Medica. Chuanxiong rhizome and Coptis chinensis are a classic herbal pair in Traditional Chinese Medicine (TCM), renowned for their effects in activating blood circulation and resolving toxicity. They are widely used to treat chest impediment and heart pain.
View Article and Find Full Text PDFLancet Rheumatol
September 2025
Bristol Royal Hospital for Children and Translational Health Sciences, Bristol, UK. Electronic address:
Background: Baricitinib has previously been shown to improve clinical response in patients with juvenile idiopathic arthritis (JIA) in the JUVE-BASIS trial. In this post-hoc analysis we aimed to identify whether pharmacodynamic changes in serum biomarkers in response to baricitinib treatment could help reaffirm the clinical utility of baricitinib in patients with JIA.
Methods: JUVE-BASIS was a randomised, double-blind, placebo-controlled, withdrawal, efficacy, safety, phase 3 trial, done in 75 centres in 20 countries.
Int Immunopharmacol
September 2025
Clinical Pharmacy Department, School of Pharmacy, Newgiza University, Giza, Egypt. Electronic address:
Ulcerative colitis (UC) is a persistent inflammatory condition marked by the destruction of the intestinal mucosal barrier, infiltration of inflammatory cells, and ulceration. M1/M2 macrophage polarization plays an imperative function in the regulation of inflammation through the nuclear factor-kappa B (NFκB) signaling pathway and modulating microRNA-155 (miR-155). Recent studies have highlighted the anti-ulcerogenic and colo-protective properties of sodium-glucose co-transporter-2 (SGLT2) inhibitors.
View Article and Find Full Text PDF